Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does UPADACITINIB Cause Prostatic specific antigen increased? 17 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 17 reports of Prostatic specific antigen increased have been filed in association with UPADACITINIB (Rinvoq). This represents 0.0% of all adverse event reports for UPADACITINIB.

17
Reports of Prostatic specific antigen increased with UPADACITINIB
0.0%
of all UPADACITINIB reports
0
Deaths
4
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From UPADACITINIB?

Of the 17 reports, 4 (23.5%) required hospitalization, and 1 (5.9%) were considered life-threatening.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 17 reports have been filed with the FAERS database.

What Other Side Effects Does UPADACITINIB Cause?

Pain (4,444) Arthralgia (3,815) Drug ineffective (3,384) Covid-19 (2,978) Rheumatoid arthritis (2,730) Pain in extremity (2,353) Fatigue (2,153) Fall (2,081) Surgery (2,037) Therapy interrupted (1,741)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which UPADACITINIB Alternatives Have Lower Prostatic specific antigen increased Risk?

UPADACITINIB vs URAPIDIL UPADACITINIB vs UREA UPADACITINIB vs URIDINE TRIACETATE UPADACITINIB vs UROFOLLITROPIN UPADACITINIB vs URSODIOL

Related Pages

UPADACITINIB Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased UPADACITINIB Demographics